title: Lung cancer: current therapies and new targeted treatments.
abstract: Lung cancer is the most frequent cause of cancer-related deaths worldwide. Every year, 1·8 million people are diagnosed with lung cancer, and 1·6 million people die as a result of the disease. 5-year survival rates vary from 4-17% depending on stage and regional differences. In this Seminar, we discuss existing treatment for patients with lung cancer and the promise of precision medicine, with special emphasis on new targeted therapies. Some subgroups, eg-patients with poor performance status and elderly patients-are not specifically addressed, because these groups require special treatment considerations and no frameworks have been established in terms of new targeted therapies. We discuss prevention and early detection of lung cancer with an emphasis on lung cancer screening. Although we acknowledge the importance of smoking prevention and cessation, this is a large topic beyond the scope of this Seminar.
authors: Department of Medicine, Division of Medical Oncology and Department of Pathology, University of Colorado Cancer Center, Denver, CO, USA; International Association for the Study of Lung Cancer, Aurora, CO, USA. Electronic address: fred.hirsch@ucdenver.edu.
authors: Fred R
authors: FR
authors: Hirsch
authors: Division of Oncology, Department of Oncology, San Luigi Hospital-Orbassano, University of Torino, Orbassano, Italy.
authors: Giorgio V
authors: GV
authors: Scagliotti
authors: Rush University Medical Center, Chicago, IL, USA.
authors: James L
authors: JL
authors: Mulshine
authors: School of Medicine, University of Colorado, Denver, CO, USA.
authors: Regina
authors: R
authors: Kwon
authors: Department of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA, USA.
authors: Walter J
authors: WJ
authors: Curran
authors: Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China.
authors: Yi-Long
authors: YL
authors: Wu
authors: Medical Oncology Department, Hospital Universitario Doce de Octubre and CNIO, Madrid, Spain.
authors: Luis
authors: L
authors: Paz-Ares
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000235:genetics / Q000401:mortality / Q000628:therapy; D003131:Combined Modality Therapy; D055088:Early Detection of Cancer; D006801:Humans; D007167:Immunotherapy; D008175:Lung Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000401:mortality / Q000628:therapy*; D009154:Mutation; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents